Trimarchi Thomas's Form 4 filing
BridgeBio Pharma, Inc. (BBIO) · filed Nov 18, 2025
- Accession no.
- 0001470831-25-000351
- Filed
- Nov 18, 2025
- Trade date
- Nov 16-17, 2025
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
This filing lists 3 non-derivative transactions. Open-market sales total $1.13M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Trimarchi ThomasCIK 0002030813 | Officer (President and CFO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 16, 2025 | Common Stock | FTax withholdingDisposed | −21,317 | $66.39 | −$1,415,235.63 | 399,764 | Direct | |
| Nov 17, 2025 | Common Stock | SSaleDisposed | −9,978 | $66.19F3 | −$660,443.82 | 389,786 | Direct | |
| Nov 17, 2025 | Common Stock | SSaleDisposed | −6,956 | $66.84F4 | −$464,939.04 | 382,830 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F3
Represents the weighted average sale price of the shares sold from $65.575 to $66.57 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
Referenced by the price of 1 transaction in Table I.
- F4
Represents the weighted average sale price of the shares sold from $66.61 to $67.26 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
Referenced by the price of 1 transaction in Table I.